Discussion on traditional Chinese medicine research strategies of different molecular subtypes of breast cancer
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 37, Issue 1, Pages: 1-9(2023)
- 作者机构：
1.上海中医药大学附属龙华医院（上海 200032）
2.上海中医药大学研究生院（上海 201203）
- 作者简介：
- 基金信息：
DOI：10.16306/j.1008-861x.2023.01.001
CLC：
扫 描 看 全 文
李斐斐,史有阳,刘胜.从乳腺癌不同分子分型谈中医药研究策略[J].上海中医药大学学报,2023,37(01):1-9.
LI Feifei,SHI Youyang,LIU Sheng.Discussion on traditional Chinese medicine research strategies of different molecular subtypes of breast cancer[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(01):1-9.
李斐斐,史有阳,刘胜.从乳腺癌不同分子分型谈中医药研究策略[J].上海中医药大学学报,2023,37(01):1-9. DOI： 10.16306/j.1008-861x.2023.01.001.
LI Feifei,SHI Youyang,LIU Sheng.Discussion on traditional Chinese medicine research strategies of different molecular subtypes of breast cancer[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(01):1-9. DOI： 10.16306/j.1008-861x.2023.01.001.
摘要
乳腺癌的发病率逐年增高，现已位居女性恶性肿瘤发病之首。近年来，中医药治疗乳腺癌的相关研究取得诸多进展，且中医外科辨病与辨证、整体与局部、内治与外治相结合的个体化治疗原则，与现代医学基于不同分子分型的精准治疗理念相符。针对乳腺癌的不同分子分型及治疗现状，从中医药抗三阴性乳腺癌（TNBC）复发转移、改善人表皮生长因子受体2（HER2）阳性乳腺癌靶向药物耐药、缓解激素受体（HR）阳性乳腺癌内分泌治疗耐药及其不良反应，归纳总结近年来中医药研究的重要成果，为乳腺癌的中医药治疗提供发展方向。
Abstract
The incidence of breast cancer is increasing year by year and now ranks first in women malignant tumors. In recent years， a lot of progress has been made in the research related to the treatment of breast cancer with traditional Chinese medicine （TCM）. In addition， the individualized treatment principle of TCM surgery， which combines disease differentiation and syndrome differentiation， holistic and localized， internal and external treatment， is consistent with the precise treatment concept based on different molecular subtypes in modern medicine. In this paper， in view of the different molecular subtypes and treatment status of breast cancer， the important research achievements of TCM researches in recent years have been summarized from anti-triple-negative breast cancer （TNBC） recurrence and metastasis， improvement of human epidermal growth factor receptor 2 （HER2）-positive breast cancer targeted drug resistance， and alleviation of hormone receptor （HR）-positive breast cancer endocrine therapy resistance and its adverse reactions with TCM. It will provide the development direction for TCM treatment of breast cancer.
关键词
乳腺癌中医药分子分型研究策略
Keywords
breast cancertraditional Chinese medicinemolecular subtypesresearch strategy
references
SIEGEL R L， MILLER K D， FUCHS H E， et al. Cancer Statistics， 2021［J］. CA Cancer J Clin， 2021， 71（1）： 7-33.
常磊，卢雯平. 基于数据挖掘探讨精准医学指导下乳腺癌分型论治的中医临床规律［J］.中国医药，2022， 17（3）： 340-344.
CHANG L，LU W P. Exploring the clinical rules of Chinese medicine in staging breast cancer under the guidance of precision medicine based on data mining［J］. China Medicine， 2022， 17（3）： 340-344.
ALBINI A，MAGNANI E，NOONAN D M. The tumor microenvironment：biology of a complex cellular and tissue society［J］. Q J Nucl Med Mol Imaging， 2010， 54（3）： 244-248.
GOLDHIRSCH A， WOOD W C，COATES A S， et al. Strategies for subtypes-dealing with the diversity of breast cancer：highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011［J］. Ann Oncol， 2011， 22（8）： 1736-1747.
刘静. 陆德铭教授运用扶正祛邪法治疗乳腺癌经验［J］.中医学报，2016， 31（4）： 470-473.
LIU J. Professor Lu Deming's experience in treating breast cancer using the method of helping the righteous and dispelling the evil［J］. Acta Chinese Medicine， 2016， 31（4）： 470-473.
张帅，刘胜. 顾氏外科乳腺癌治验［J］.吉林中医药，2017， 37（3）： 241-244.
ZHANG S，LIU S. Gu’s surgical breast cancer treatment experience［J］. Jilin Journal of Chinese Medicine， 2017， 37（3）： 241-244.
薛晓红，刘胜. 中医药治疗乳腺癌的疗效与思考［J］.上海中医药大学学报，2003， 17（2）： 14-16.
XUE X H，LIU S. Efficacy and reflection of Chinese medicine in the treatment of breast cancer ［J］. Academic Journal of Shanghai University of Traditional Chinese Medicine， 2003， 17（2）： 14-16.
AL-MAHMOOD S，SAPIEZYNSKI J，GARBUZENKO O B，et al. Metastatic and triple-negative breast cancer：challenges and treatment options［J］.Drug Deliv Transl Res， 2018， 8（5）： 1483-1507.
WAKS A G，WINER E P. Breast Cancer Treatment：A Review［J］.JAMA， 2019， 321（3）： 288-300.
GONG Y，JI P，YANG Y S，et al. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets［J］. Cell Metab， 2021， 33（1）： 51-64.
JIANG Y Z，MA D，SUO C，et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers：Subtypes and Treatment Strategies［J］. Cancer Cell， 2019， 35（3）： 428-440.
辛颖，刘胜，秦悦农，等. 中药三阴方治疗三阴性乳腺癌的回顾性队列研究［J］.上海中医药杂志，2021， 55（5）： 63-66.
XIN Y，LIU S，QIN Y N，et al. A retrospective cohort study of Chinese medicine Sanyin formula for the treatment of triple-negative breast cancer ［J］.Shanghai Journal of Traditional Chinese Medicine， 2021， 55（5）： 63-66.
王怡，秦悦农，孙霃平，等. 乳癌术后三阴方干预三阴性乳腺癌术后的临床疗效观察［J］.中华中医药杂志，2020， 35（8）： 4242-4246.
WANG Y，QIN Y N，SUN KESHE P，et al. Clinical efficacy of postoperative triple-negative breast cancer formula intervention for postoperative triple-negative breast cancer［J］. Chinese Journal of Traditional Chinese Medicine and Pharmcy， 2020， 35（8）： 4242-4246.
WU C，SUN C，LIU G，et al. Effectiveness of the Sanyin Formula Plus Chemotherapy on Survival in Women With Triple-Negative Breast Cancer：A Randomized Controlled Trial［J］. Front Oncol， 2022， 12： 850155.
罗楚凡，刘宁远，张静，等. 蒌慈散结方防治三阴性乳腺癌复发转移的临床观察［J］.北京中医药，2020， 39（10）： 1022-1027.
LUO CF，LIU N Y，ZHANG J，et al. Clinical observation on the prevention and treatment of recurrence and metastasis of triple-negative breast cancer with the formula of Pou Cai San Kao［J］.Beijing Journal of Traditional Chinese Medicine， 2020， 39（10）： 1022-1027.
张静. 蒌慈散结方预防三阴性乳腺癌复发转移475例临床研究［D］.北京：北京中医药大学，2021.
ZHANG J. Clinical study on prevention of recurrence and metastasis of triple-negative breast cancer in 475 cases with Piper's Tzu-San-Knot formula［D］.Beijing：Beijing University of Traditional Chinese Medicine， 2021.
张佳慧. 多中心前瞻性评价中医药对三阴性乳腺癌术后复发转移队列研究［D］.北京：北京中医药大学，2020.
ZHANG J H. Multicenter prospective evaluation of Chinese medicine on postoperative recurrent metastasis in triple-negative breast cancer cohort study［D］.Beijing：Beijing University of Traditional Chinese Medicine， 2020.
孟慧. 中医药预防三阴性乳腺癌患者术后复发转移的干预研究［D］.北京：北京中医药大学，2018.
MENG H. Interventional study on the prevention of postoperative recurrence and metastasis in triple-negative breast cancer patients by Chinese medicine［D］.Beijing：Beijing University of Traditional Chinese Medicine， 2018.
陈秀杰. 放化疗联合槐耳颗粒对三阴性乳腺癌术后患者预后及生存质量影响的临床研究［D］.沈阳：中国医科大学，2021.
CHEN X J. Clinical study on the effect of radiotherapy combined with Sophora granules on the prognosis and survival quality of patients with triple negative breast cancer after surgery［D］.Shenyang： China Medical University， 2021.
董晶，王邦才，施航. 复方土贝母制剂联合化疗治疗晚期三阴性乳腺癌临床观察［J］.浙江中西医结合杂志，2019， 29（3）： 203-205.
DONG J，WANG B C，SHI H. Clinical observation of compound tupelo preparation combined with chemotherapy in the treatment of advanced triple-negative breast cancer［J］.Zhejiang Journal of Integrative Traditional Chinese and Western Medicine， 2019， 29（3）： 203-205.
王鹏飞. 复方斑蝥胶囊联合复方红豆杉方加减治疗三阴乳腺癌临床观察［J］.光明中医，2018， 33（10）： 1435-1437.
WANG P F. Clinical observation on the treatment of triple-negative breast cancer with the combination of compound zebrano capsule and compound red bean curd formula plus reduction［J］.Guangming Journal of Chinese Medicine， 2018， 33（10）： 1435-1437.
PICCART M，PROCTER M，FUMAGALLI D，et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial：6 Years’ Follow-Up［J］. J Clin Oncol， 2021， 39（13）： 1448-1457.
徐琦，房德敏. 曲妥珠单抗耐药机制的研究进展［J］.天津药学，2021， 33（6）： 65-69.
XU Q，FANG D M. Research progress on the mechanism of trastuzumab resistance［J］. Tianjin Pharmcy， 2021， 33（6）： 65-69.
刘凯乐，邓海滨. 免疫细胞耗竭对带瘤生存的影响及中医扶正法干预治疗研究进展［J］.河北中医，2022， 44（2）： 346-352.
Liu Kaille，Deng Binhai. Effect of immune cell depletion on survival with tumor and research progress of TCM Fu Zheng method intervention treatment［J］.Hebei Journal of Traditional Chinese Medicine，2022，44（2）：346-352.
李慧杰，齐元富，李秀荣. 基于肿瘤免疫编辑理论探讨扶正抗癌法在肺癌治疗中的应用［J］.中医杂志，2017，58（8）：651-653.
LI H J，QI Y F，LI X R. Exploring the application of Fu Zheng and anti-cancer method in the treatment of lung cancer based on tumor immune editing theory［J］.Journal of Traditional Chinese Medicine， 2017， 58（8）： 651-653.
胥孜杭，朱杨壮壮，张飞，等. 泽漆汤对肺癌原位模型小鼠的抑制作用［J］.中国实验方剂学杂志，2019， 25（14）： 6-12.
Xu Z H， Zhu Y Z Z，Zhang F，et al. Inhibitory effect of Zechi Tang on mice with in situ model of lung cancer［J］. Chinese Journal of Experimental Traditional Medical Formulae， 2019， 25（14）： 6-12.
王晓燕，刘畅，朴星虎，等. 大黄素通过调节体外扩增NK细胞杀伤肺癌A549细胞的实验研究［J］.辽东学院学报（自然科学版），2019， 26（2）： 102-106.
WANG X Y， LIU C， PARK X H，et al. Experimental study on the killing of lung cancer A549 cells by rhodopsin through regulation of in vitro expansion of NK cells［J］. Journal of Eastern Liaoning University （Natural Science Edition）， 2019， 26（2）： 102-106.
阎学伟，龚陈媛，祝晓雯，等. 玫瑰树碱促进NK细胞识别与杀伤非小细胞肺癌细胞的研究［J］.中国药理学通报，2020， 36（9）： 1240-1247.
YAN X W， GONG C Y， ZHU X W， et al. Rose bengal promotes the recognition and killing of non-small cell lung cancer cells by NK cells［J］. Chinese Pharmacological Bulletin， 2020， 36（9）： 1240-1247.
李溪. 姜黄素调控肿瘤相关巨噬细胞极化抑制卵巢癌恶性行为及其机制研究［D］.上海：海军军医大学，2019.
LI X. Curcumin regulates tumor-associated macrophage polarization to inhibit malignant behavior of ovarian cancer and its mechanism［D］. Shanghai： Naval Medical University， 2019.
YANG R，XIE Y，LI Q，et al. Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization［J］.Biomed Pharmacother， 2021，141：111883.
BAMODU O A，KUO K T，WANG C H，et al. Astragalus polysaccharides（PG2） Enhances the M1 Polarization of Macrophages，Functional Maturation of Dendritic Cells，and T Cell-Mediated Anticancer Immune Responses in Patients with Lung Cancer［J］. Nutrients， 2019， 11（10）： 2264.
高静. 基于肿瘤相关巨噬细胞研究人参扶正固本抗肿瘤机制［D］.南京：南京中医药大学，2016.
GAO J. Study of anti-tumor mechanism of ginseng based on tumor-associated macrophages to support the essence［D］.Nanjing：Nanjing University of Traditional Chinese Medicine， 2016.
冯磊，李响，孟繁平，等. 炙甘草多糖对小鼠巨噬细胞再极化的影响［J］.中国免疫学杂志，2020， 36（9）： 1080-1085.
FENG L，LI R，MENG F P，et al. Effect of roasted licorice polysaccharide on the repolarization of mouse macrophages［J］.Chinese Journal of Immunology， 2020， 36（9）： 1080-1085.
FISZMAN G L，JASNIS M A. Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer［J］.Int J Breast Cancer， 2011， 2011： 352182. doi： 10.4061/2011/352182http://dx.doi.org/10.4061/2011/352182.
KILLOCK D. Targeted therapy：Leveraging ADCC to enhance anti-HER2 therapy［J］. Nat Rev Clin Oncol， 2017， 14（4）： 200.
SWAIN S M，BASELGA J，KIM S B，et al. Pertuzumab，trastuzumab，and docetaxel in HER2-positive metastatic breast cancer［J］. N Engl J Med， 2015， 372（8）： 724-734.
WILKEN J A. MAIHLE N J. Primary trastuzumab resistance：new tricks for an old drug［J］. Ann N Y Acad Sci， 2010， 1210： 53-65.
WANG Z，YIN C， LUM L G， et al. Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity［J］. J Hematol Oncol， 2021， 14（1）： 204.
UPTON R，BANUELOS A，FENG D，et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance［J］.Proc Natl Acad Sci U S A， 2021， 118（29）： e2026849118.
SHI Y，FAN X，DENG H，et al. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages［J］. J Immunol， 2015， 194（9）： 4379-4386.
SCHMID P， CORTES J， PUSZTAI L，et al. Pembrolizumab for Early Triple-Negative Breast Cancer［J］. N Engl J Med， 2020， 382（9）： 810-821.
MANDÓ P， RIVERO S G， RIZZO M M， et al. Targeting ADCC： A different approach to HER2 breast cancer in the immuno-therapy era［J］. Breast， 2021， 60： 15-25.
李斐斐，史有阳，张洋，等. 基于HER-2阳性乳腺癌治疗难点探讨中医药治疗特色及研究进展［J］.中国实验方剂学杂志，2022［2022-06-21］：1-7. doi：10.13422/j.cnki.syfjx.20221725http://dx.doi.org/10.13422/j.cnki.syfjx.20221725.
LI F F，SHI Y Y，ZHANG Y，et al. Exploring the characteristics of Chinese medicine treatment and research progress based on the difficulties in the treatment of HER-2 positive breast cancer［J］.Chinese Journal of Experimental Traditional Medical Formulae， 2022［2022-06-21］：1-7. doi：10.13422/j.cnki.syfjx.20221725http://dx.doi.org/10.13422/j.cnki.syfjx.20221725.
COLE M P， JONES C T， TODD I D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474［J］. Br J Cancer， 1971， 25（2）： 270-275.
邹辣，吴绮楠. 激素受体阳性乳腺癌的内分泌治疗［J］.重庆医科大学学报，2021， 46（1）： 91-96.
ZOU J，WU E N. Endocrine therapy for hormone receptor-positive breast cancer［J］. Journal of Chongqing Medical University， 2021， 46（1）： 91-96.
HANKER A B，SUDHAN D R，ARTEAGA C L. Overcoming Endocrine Resistance in Breast Cancer［J］. Cancer Cell， 2020， 37（4）： 496-513.
SARFSTEIN R，NAGARAJ K，LEROITH D，et al. Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells［J］. Cells， 2019， 8（22）： 1499.
车焕莉，闫会苓，卢雯平. 疏肝益肾方对人乳腺癌TAM耐药细胞株MCF-7 TAM-R的作用及其机制的研究［J］.四川中医，2014， 32（8）： 50-52.
CHE H L，YAN H L，LU W P. Study on the effect of liver-sparing and kidney-yielding formula on human breast cancer TAM-resistant cell line MCF-7 TAM-R and its mechanism［J］. Journal of Sichuan Traditional Chinese Medicine， 2014， 32（8）： 50-52.
WANG Y，YUE W，LANG H，et al. Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine［J］. Integr Cancer Ther， 2021， 20： 15347354219 96822.
桂越蓉，王烁，董军，等. 基于网络药理学探讨益肾清肝方逆转乳腺癌内分泌治疗耐药机制［J］.中国中医药信息杂志，2022， 29（12）： 30-37.
GUI Y R， WANG S， DONG J， et al. Network-based pharmacology to explore the mechanism of reversing drug resistance to endocrine therapy in breast cancer with Yi kidney and liver clearing formula［J］. Chinese Journal of Information on Traditional Chinese Medicine， 2022， 29（12）： 30-37.
龙成根，凌华海，许德明，等. 激素受体阳性乳腺癌长期内分泌治疗不良反应的观察［J］.中国实用医药，2020， 15（21）： 28-30.
LONG C G，LING H H，XU D M，et al. Observation of adverse effects of long-term endocrine therapy in hormone receptor-positive breast cancer［J］. Chinese Practical Medicine， 2020， 15（21）： 28-30.
LI L，WANG R，ZHANG A，et al. Evidence on Efficacy and Safety of Chinese Medicines Combined Western Medicines Treatment for Breast Cancer With Endocrine Therapy［J］. Front Oncol， 2021， 11： 661925.
GE A Q， YANG K L， DENG X G. The efficacy and safety of Xihuang Pill/capsule in adjuvant treatment of breast cancer：A systematic review and meta-analysis of 26 randomized controlled trials［J］. J Ethnopharmacol， 2022， 295： 115357.，
蒋荣飞. 柴胡加龙骨牡蛎汤加减干预乳腺癌内分泌治疗后类更年期综合征的临床观察［D］.天津：天津中医药大学，2021.
JIANG R F. Clinical observation of clinical observation of menopause-like syndrome after endocrine treatment for breast cancer with Chai Hu plus Long Bone Oyster Tang plus reduction［D］. Tianjin： Tianjin University of Traditional Chinese Medicine，2021.
李奇. 益肾疏肝汤改善乳腺癌内分泌治疗后类围绝经期综合征的疗效观察［D］.北京：中国中医科学院，2018.
LI Q. The efficacy of Yi kidney and liver dredging soup in improving perimenopausal syndrome of class after endocrine therapy for breast cancer ［D］. Beijing： China Academy of Chinese Medical Sciences， 2018.
翁婷婷. 补肾壮骨解毒方对乳腺癌内分泌治疗相关性骨质疏松症的临床疗效观察［D］.南京：南京中医药大学，2021.
WENG T T. Clinical efficacy of kidney strengthening and bone detoxification formula on endocrine therapy-associated osteoporosis in breast cancer［D］. Nanjing：Nanjing University of Traditional Chinese Medicine， 2021.
孙铮迪. 加味左归丸对乳腺癌芳香化酶抑制剂所致骨质疏松症的临床研究［D］.济南：山东中医药大学，2018.
SUN Z D. Clinical study on osteoporosis caused by aromatase inhibitors in breast cancer with the addition of Zuo Gui Wan［D］. Jinan：Shandong University of Traditional Chinese Medicine，2018.
MAO J J，XIE S X，FARRAR J T，et al. A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use［J］. Eur J Cancer， 2014， 50（2）： 267-276
MAO J J，BOWMAN M A，XIE S X，et al.Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors：A Randomized Placebo-Controlled Trial［J］. J Clin Oncol， 2015， 33（31）： 3615-3620.
张秀丽. 揿针调节乳腺癌内分泌治疗引起脂代谢异常临床研究［D］.北京：北京中医药大学，2020.
ZHANG X L. Clinical study on the regulation of abnormal lipid metabolism caused by endocrine treatment of breast cancer by snap-needle［D］.Beijing：Beijing University of Traditional Chinese Medicine， 2020.
刘少玉. 磁珠耳穴改善乳腺癌内分泌治疗相关类围绝经期综合征临床研究［D］.北京：北京中医药大学，2021.
LIU S Y.Clinical study on the improvement of perimenopausal syndrome in the class associated with endocrine therapy for breast cancer by magnetic bead ear acupuncture［D］.Beijing：Beijing University of Traditional Chinese Medicine， 2021.
陈力新. 耳穴贴压联合中药改善乳腺癌内分泌治疗后血管舒缩症状临床疗效观察［D］.上海：上海中医药大学，2020.
CHEN L X. Clinical efficacy of auricular acupressure combined with traditional Chinese medicine to improve vasodilatory symptoms after endocrine therapy for breast cancer［D］. Shanghai：Shanghai University of Traditional Chinese Medicine， 2020.
马兰. 中药治疗乳腺癌内分泌药物引起不良反应的方药规律研究［D］.沈阳：辽宁中医药大学，2021.
MA L. Study on the prescription pattern of adverse reactions caused by endocrine drugs in the treatment of breast cancer with Chinese medicine［D］.Shenyang：Liaoning University of Traditional Chinese Medicine， 2021.
0
Views
367
下载量
0
CSCD
0
CNKI被引量
- L-PDFDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
- Total Visits：10154 Visits Today：17